Cannabidiol Is a Novel Modulator of Bacterial Membrane Vesicles
1Cellular and Molecular Immunology Research Centre, School of Human Sciences, London Metropolitan University, London, United Kingdom
2School of Life, Health and Chemical Sciences, The Open University, Milton Keynes, United Kingdom
3Bioscience Research Group, Extracellular Vesicle Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom
4School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom
5Research Centre for Optimal Health, School of Life Sciences, University of Westminster, London, United Kingdom
6GW Pharmaceuticals Research, Cambridge, United Kingdom
7Tissue Architecture and Regeneration Research Group, School of Life Sciences, University of Westminster, London, United Kingdom
*Correspondence: Sigrun Lange s.lange@westminster.ac.ukAbstract
Membrane vesicles (MVs) released from bacteria participate in cell communication and host-pathogen interactions. Roles for MVs in antibiotic resistance are gaining increased attention and in this study we investigated if known anti-bacterial effects of cannabidiol (CBD), a phytocannabinoid from Cannabis sativa, could be in part attributed to effects on bacterial MV profile and MV release. We found that CBD is a strong inhibitor of MV release from Gram-negative bacteria (E. coli VCS257), while inhibitory effect on MV release from Gram-positive bacteria (S. aureus subsp. aureus Rosenbach) was negligible. When used in combination with selected antibiotics, CBD significantly increased the bactericidal action of several antibiotics in the Gram-negative bacteria. In addition, CBD increased antibiotic effects of kanamycin in the Gram-positive bacteria, without affecting MV release. CBD furthermore changed protein profiles of MVs released from E. coli after 1 h CBD treatment. Our findings indicate that CBD may pose as a putative adjuvant agent for tailored co-application with selected antibiotics, depending on bacterial species, to increase antibiotic activity, including via MV inhibition, and help reduce antibiotic resistance.
Introduction
Outer membrane vesicles (OMVs) and membrane vesicles (MVs) are released from Gram-negative and Gram-positive bacteria and participate in inter-bacterial communication, including via transfer of cargo molecules (Dorward and Garon, 1990; Li et al., 1998; Fulsundar et al., 2014; Jan, 2017; Toyofuku et al., 2019). MVs are released in greater abundance from Gram-negative, than Gram-positive bacteria and their production seems crucial for bacterial survival and forms part of the stress response (McBroom and Kuehn, 2007; Macdonald and Kuehn, 2013; Jan, 2017). Gram-negative bacteria generate, in addition to common one-bilayer vesicles (OMV), also double-bilayer vesicles (O-IMVs), and in some stress conditions other types of MVs (Pérez-Cruz et al., 2016) and therefore we will use the umbrella term “membrane vesicles” (MVs) hereafter. MVs are important in biofilm formation and dissemination of toxins in the host (Wang et al., 2015; Cooke et al., 2019). MVs participate in host-pathogen interactions (Gurung et al., 2011; Koeppen et al., 2016; Bitto et al., 2017, 2018; Codemo et al., 2018; Turner et al., 2018; Cecil et al., 2019) and may also be involved in antibiotic resistance, for instance by protecting biofilms from antibiotics via increased vesiculation (Manning and Kuehn, 2011). Furthermore, MVs from Porphyromonas gingivalis have been linked to metabolic remodeling in the host (Fleetwood et al., 2017), while MVs from Neisseria gonorrhoeae have been shown to target host mitochondria and to induce macrophage death (Deo et al., 2018). Besides roles for cellular and bacterial communication, the use of MVs as nano-carriers for various compounds, including for antibiotic and vaccine delivery, has also raised considerable interest in the research community (Gnopo et al., 2017; Rüter et al., 2018; Tan et al., 2018; Wang et al., 2018).
The regulation of bacterial MV biogenesis and release may therefore be of great importance, both in relation to inter-bacterial communication, including biofilm formation, their host interactions as commensals, as well as in host-pathogen interactions and in antibiotic resistance.
Cannabidiol (CBD) is a phytocannabinoid from Cannabis sativa with anti-inflammatory (Martin-Moreno et al., 2011), anti-cancerous (Pisanti et al., 2017; Kosgodage et al., 2018) and anti-bacterial activity (Hernández-Cervantes et al., 2017). While immunoregulatory roles for cannabinoids have been reported in infectious disease (reviewed in Hernández-Cervantes et al., 2017), and C. sativa has been identified as a natural product with a capability of controlling bacterial infections, including a strong anti-bacterial activity against antibiotic resistant strains (Appendino et al., 2008), a link between CBD and bacterial MV release has hitherto not been investigated.
As our recent work identified CBD as a potent inhibitor of extracellular vesicle (EV) release in eukaryotes (Kosgodage et al., 2018; Gavinho et al., 2019), we sought to investigate whether CBD may work via phylogenetically conserved pathways, involving bacterial MV release from bacteria. As we, and other groups, have previously shown that cancer cells can be sensitized to chemotherapeutic agents via various EV-inhibitors (Jorfi et al., 2015; Koch et al., 2016; Muralidharan-Chari et al., 2016; Kosgodage et al., 2017), including CBD (Kosgodage et al., 2018, 2019), we sought to establish whether in bacteria, similar putative MV modulatory effects could be utilized to sensitize bacteria to antibiotics.
Materials and Methods
MV Isolation From E. coli VCS257 and S. aureus subsp. aureus Rosenbach
E. coli (VCS257, Agilent, La Jolla, CA) and S. aureus subsp. aureus Rosenbach (ATCC 29247, USA) static cultures were grown in Luria-Bertani (LB) broth for 24 h at 37°C. The growth phase before vesicle isolation was exponential; the volume of the cultures was 20 ml. For MV isolation, ultracentrifugation and nanoparticle tracking analysis (NTA) were used based on previously established methods by other groups (McCaig et al., 2013; Klimentova and Stulik, 2015; Roier et al., 2016).
E. coli and S. aureus cultures were maintained by plating on Mueller-Hinton agar plates and weekly sub-culturing was performed according to previously established methods (Iqbal et al., 2013).
Before MV isolation, all bacterial growth medium (LB broth) was pre-treated before use by ultracentrifugation at 100,000 g for 24 h to ensure minimum contamination with extracellular vesicles (EVs) from the medium (Kosgodage et al., 2017).
For MV isolation, bacteria were grown in EV-free medium (as described above) for 24 h at 37°C, the culture medium was collected and centrifuged once at 400 g for 10 min for removal of cells, followed by centrifugation at 4,000 g for 1 h at 4°C to remove cell debris. The resultant supernatant was then centrifuged for 1 h at 100,000 g at 4°C and the isolated MV pellet was resuspended in Dulbecco's phosphate buffered saline (DPBS; ultracentrifuged and sterile filtered using a 0.22 μm filter) and centrifuged again at 100,000 g for 1 h at 4°C. The resulting MV pellet was sterile filtered (0.45 μm) once and then resuspended in sterile filtered DPBS. The quantitative yield of vesicles was ~6.5 × 109 MVs per liter of culture. The isolated MV pellets were then either used immediately, or stored at −80°C for further experiments.
Transmission Electron Microscopy (TEM) Imaging of Bacterial MVs
A suspension of isolated MVs (1.4 × 108 MVs/ml) was used for TEM imaging. MV samples (10 μL) were applied to mesh copper grids, prepared with glow discharged carbon support films, and incubated for 2 min. The grids were then washed five times with 50 μl of 1 % aqueous uranyl acetate. Grids were left to dry for 5 min before being viewed. Micrographs were taken with a JEOL JEM 1230 transmission electron microscope (JEOL, Japan) operated at 80 kV at a magnification of 80,000 to 100,000. Digital images were recorded using a Morada CCD camera (EMSIS, Germany) and processed via iTEM (EMSIS).
Western Blotting
Protein was isolated from MV pellets using Bacterial Protein Extraction Reagent (B-PER, ThermoFisher Scientific, U.K.), pipetting gently and shaking the pellets on ice for 2 h, where after samples were centrifuged at 16,000 g at 4°C for 20 min and the resulting supernatant collected for protein analysis. Samples were prepared in 2x Laemmli buffer, boiled at 95°C for 5 min, electrophoresed by SDS-PAGE on 4–20 % TGX gels (BioRad, U.K.), followed by semi-dry Western blotting. Approximately 10 μg of protein was loaded per lane and even protein transfer was assessed by Ponceau S staining (Sigma, U.K.). Blocking of membranes was performed for 1 h at room temperature (RT) in 5 % BSA in TBS-T. The membranes were then incubated with the anti-OmpC (Outer-membrane protein C antibody; orb6940, Biorbyt, U.K.; diluted 1/1000 in TBS-T) overnight at 4°C, followed by washing in TBS-T and incubation for 1 h in anti-rabbit-HRP conjugated secondary antibody at RT. Visualization was performed using ECL (Amersham, U.K.) and the UVP BioDoc-ITTM System (U.K.).
Nanoparticle Tracking Analysis for Assessment of MV Release From E. coli VCS257 and S. aureus subsp. aureus Rosenbach
MVs were isolated from control and CBD-treated bacterial cultures as described above. Nanoparticle tracking analysis (NTA) was performed using the Nanosight LM10 (Malvern, U.K.), equipped with a 405 nm diode laser and a sCMOS camera. MV pellets were resuspended in equal volumes (100 μl) of DPBS before NTA analysis to ensure comparable analysis of quantification. Before application, samples were diluted 1:50 in sterile-filtered EV-free DPBS and applied at a constant flow rate, maintaining the number of particles in the field of view in the range of 20–40 with a minimum concentration of samples at 5 × 107 particles/ml. Camera settings were according to the manufacturer's instructions (Malvern), five 60 s videos per sample were recorded and replicate histograms averaged. Each experiment was repeated three times.
CBD-Mediated MV Release Inhibition in E. coli VCS257 and S. aureus subsp. aureus Rosenbach
E. coli and S. aureus cultures were cultivated using EV-free Müeller-Hinton broth for 24 h. An inoculate of 0.1 ml of bacteria, in a 20 ml culture volume of bacterial growth medium (Luria-Bertani (LB) broth), were grown at exponential phase overnight, as assessed by OD600. The bacterial cells were then washed using DPBS at 4,000 g for 10 min and seeded in 1.5 ml triplicates in micro centrifuge tubes. For treatment with CBD, CBD (GW research Ltd) was applied at concentrations of 1 or 5 μM and incubated with the bacterial cultures for 1 h at 37°C. Treatments were performed in triplicates, including DMSO as a control. MV isolation following CBD and control treatment was carried out using step-wise centrifugation and ultracentrifugation as before. Changes in MV release were assessed by quantifying numbers of MVs by NTA analysis as described above, with each experiment repeated three times. Cell viability was assessed before the start of every experiment and after treatment with CBD compared to controls determined by colony forming unit (CFU) measurement.
Disc Diffusion Test for Assessment of CBD-Mediated Enhancement of Antibiotic Treatment
Discs were impregnated with the following antibiotics (all from Sigma-Aldrich): colistin (10 μg/ml), rifampicin (15 μg/ml), erythromycin (50 μg/ml), kanamycin (1,000 μg/ml) and vancomycin (5 μg/ml). Concentration of the antibiotics used was based on previously published and established MIC values (Maclayton et al., 2006; Moskowitz et al., 2010; Kshetry et al., 2016; Rojas et al., 2017; Goldstein et al., 2018). E. coli and S. aureus agar plates were prepared for the disc diffusion test (Iqbal et al., 2013) by soaking a sterile paper disc in 5 μM CBD and placing it in the middle of the agar plate, while the impregnated antibiotic discs were placed equidistant to the CBD disc. Zones of inhibition were assessed after 24 h using the Kirby-Bauer test.
Proteomic Analysis of MVs Released From CBD Treated and Control Untreated E. coli VCS257
To assess differences in E. coli VCS257 MV protein composition in response to CBD treatment, MVs were isolated as before, after 1 h treatment with 1 μM or 5 μM CBD treatment or control untreated, respectively. MVs were assessed by SDS-PAGE (using 4–20 % gradient TGX gels, BioRad, U.K.) and silver staining using the BioRad Silver Stain Plus Kit (1610449, BioRad, U.K.), according to the manufacturer's instructions (BioRad). For assessment of proteomic changes, MVs were subjected to liquid chromatography-mass spectrometry (LC-MS/MS) analysis. MVs from CBD treated, vs. non-treated E. coli were run 1 cm into a SDS-PAGE gel and the whole protein lysate cut out as one band, whereafter it was processed for proteomic analysis (carried out by Cambridge Proteomics, U.K.). Peak list files were submitted to Mascot (in-house, Cambridge Center for Proteomics) using the following database: Uniprot_Escherichia_coli_20180613 (4324 sequences; 1357163 residues).
Statistical Analysis
Histograms and graphs were prepared and statistical analysis was performed using GraphPad Prism version 8 (GraphPad Software, San Diego, U.S.A.). One-way ANOVA and Student's t-test analysis were performed, followed by Tukey's post-hoc analysis. Histograms represent mean of data, with error bars representing standard error of mean (SEM). Significant differences were considered as p ≤ 0.05.
Results
Characterization of MVs From E. coli VCS257 and S. aureus subsp. aureus Rosenbach
Isolated MVs were assessed by morphology using transmission electron microscopy (TEM), revealing a poly-dispersed population in the size range of mainly 20–230 nm in diameter for E. coli, including MVs showing inner and outer membranes (Figure 1A.1), and characteristic one layer membranes for S. aureus MVs, which were in the 37–300 nm range (Figure 1A.2). Nanoparticle tracking analysis (NTA) verified that the majority of the vesicle population fell in a similar size range under standard culture conditions (mode 143.3 nm; SD ± 72.3 nm for E. coli (Figure 1A.1) and 141.4 nm; SD ± 7.3 nm for S. aureus (Figure 1A.2). Furthermore, Western blotting showed positive for the MV specific marker OmpC (Figure 1A).
Effects of CBD on Membrane Vesicle Release From E. coli VCS257 and S. aureus subsp. aureus Rosenbach
CBD changed the MV release profile from E. coli compared to control treatment (Figures 1B–D). Modal size of MVs released from E. coli was significantly increased (p = 0.01) after 1 μM CBD treatment, compared to control treated cells, while 5 μM CBD treatment did not have statistically significant effects on MV size (p = 0.0685). Effects on modal size of vesicles released from E. coli between the two doses of CBD was also not statistically significant (p = 0.0643; Figure 1D).
CBD had a significant inhibitory effect (p < 0.0001) on total MV release from E. coli VCS257 at both concentrations tested (1 and 5 μM, respectively; Figure 2A). In addition, the lower dose of CBD (1 μM) had stronger MV-inhibitory effects (73 % reduction, p < 0.0001) than 5 μM CBD (54 % reduction, p < 0.0001; Figure 2A) and resulted in a markedly increased peak at 500 nm (Figure 1B), which otherwise was negligible in the control (Figure 1A) and 5 μM CBD (Figure 1C) treated E. coli.
Effects of CBD on E. coli VCS257 MVs was furthermore assessed by TEM, verifying the presence of fewer vesicles per field and showing some change in vesicle size and morphology after CBD (Supplementary Figures 2A–C).
Contrary to what was observed for the Gram-negative E. coli, CBD treatment (5 μM) had no significant effect on MV release from the Gram-positive bacterium S. aureus subsp. Aureus Rosenbach (p > 0.1; Figure 2B).
Effects of CBD on Bacterial Viability of E. coli VCS257 and S. aureus subsp. aureus Rosenbach
CBD had negligible effect on E. coli cell viability after 24 h incubation with the lower 1 μM dose, while an 11 % (p = 0.0161) reduction in cell viability was observed in response to 5 μM CBD, but no significant effect was observed on S. aureus cell viability, as assessed by disk diffusion test (Supplementary Figure 1).
CBD Treatment Affects Antibiotic Sensitivity in E. coli VCS257
CBD treatment (5 μM), when applied in combination with a range of antibiotics tested, was found to sensitize E. coli VCS257 to selected antibiotics, as assessed by an increase in the radius of zone of inhibition, using the disk diffusion test (Figure 3). Significantly enhanced antibacterial effects were found for erythromycin (35 % increase; p = 0.006), rifampicin (50 % increase; p = 0.0007) and vancomycin (100 % increase; p < 0.0001), when combined with CBD treatment (5 μM), compared to antibiotic treatment alone. Notably, vancomycin alone did not have bactericidal effects on E. coli, but only in the presence of CBD. Antibacterial effects of kanamycin were increased by 18 % but this was not statistically significant compared to antibiotic alone (p = 0.09). Zone of inhibition with CBD treatment only was also observed in the E. coli plates (Figure 3), but this was significantly lower than when CBD was combined with antibiotics, except for vancomycin. The zone of inhibition for E. coli caused by antibiotic treatment only, vs. CBD alone, differed also significantly for erythromycin (p = 0.0010), vancomycin (p = 0.0158), rifampicin (p = 0.0003) and kanamycin (p = 0.0008), but not for colistin (p = 0.224). Therefore, while CBD showed some anti-bacterial activity against E. coli when applied in isolation, this was significantly lower than observed for the antibiotics alone (except for vancomycin which did not show antibacterial activity while CBD did). However, when applied in combination, CBD increased bactericidal effects of all antibiotics tested, except for colistin.
CBD-Mediated Effects on Antibiotic Sensitivity in S. aureus subsp. aureus Rosenbach
When added to S. aureus subsp. aureus Rosenbach, 5 μM CBD increased the antibiotic activity of kanamycin (30 %; p = 0.0028), as assessed by increased radius of zone around the diffusion disk (Figure 4). CBD did not enhance anti-bacterial activity for the other antibiotics tested and reduced antibacterial effects of both erythromycin and rifampicin (p = 0.0325 and p = 0.0001, respectively). Importantly, there was no halo observed around the diffusion disk containing CBD alone in the S. aureus plates, indicating no bactericidal effects of CBD on this strain of S. aureus.
Effects of CBD Treatment on Protein Profiles of MVs Released From E. coli VCS257
Protein composition of MVs was assessed in MVs isolated from E. coli VCS257 after 1 h treatment with 1 μM and 5 μM CBD, respectively, compared to non-treated E. coli MVs, using SDS-PAGE silver stained gels and LC-MS/MS analysis. Silver stained gels revealed some band differences between the three conditions (Figure 5A). Proteins were further analyzed by LC-MS/MS and peak list files submitted to Mascot (in-house, Cambridge Center for Proteomics, Uniprot_Escherichia_coli_20180613). Hits are listed in Tables 1–3. Compared to untreated MVs, five protein hits were absent in MVs released from the 1 μM CBD treated E. coli and four protein hits were absent in MVs released from the 5 μM CBD treated E. coli, respectively (Table 1 and Figure 5B). When comparing the two CBD treatments, 26 protein hits were specific to the E. coli MVs following 1 μM CBD treatment (Table 2 and Figure 5B) while 68 protein hits were unique to the MVs released from E. coli treated with 5 μM CBD (Table 3 and Figure 5B).
| Protein name | Symbol | Score (p < 0.05)‡ | CBD 1 μM | CBD 5 μM |
|---|---|---|---|---|
| Glutamate decarboxylase alpha | P69908|DCEA_ECOLI | 37 | – | + |
| 2-oxoglutarate dehydrogenase E1 component | P0AFG3|ODO1_ECOLI | 36 | + | – |
| RNA chaperone ProQ | P45577|PROQ_ECOLI | 32 | – | + |
| Uncharacterized protein YffS | P76550|YFFS_ECOLI | 29 | – | + |
| Serine transporter | P0AAD6|SDAC_ECOLI | 26 | + | – |
| Fumarate and nitrate reduction regulatory protein | P0A9E5|FNR_ECOLI | 26 | – | – |
| Uncharacterized protein YcaQ | P75843|YCAQ_ECOLI | 22 | – | – |
| Protein name | Symbol | Score (p < 0.05)‡ |
|---|---|---|
| Glutamate decarboxylase beta | P69910|DCEB_ECOLI | 230 |
| Tryptophan synthase alpha chain | P0A877|TRPA_ECOLI | 85 |
| 2-oxoglutarate dehydrogenase E1 component | P0AFG3|ODO1_ECOLI | 70 |
| Uncharacterized protein YgaU | P0ADE6|YGAU_ECOLI | 67 |
| Spermidine/putrescine-binding periplasmic protein | P0AFK9|POTD_ECOLI | 67 |
| Serine transporter | P0AAD6|SDAC_ECOLI | 57 |
| Inorganic pyrophosphatase | P0A7A9|IPYR_ECOLI | 56 |
| Succinate dehydrogenase flavoprotein subunit | P0AC41|SDHA_ECOLI | 54 |
| NADH-quinone oxidoreductase subunit A | P0AFC3|NUOA_ECOLI | 53 |
| Periplasmic dipeptide transport protein | P23847|DPPA_ECOLI | 49 |
| Uncharacterized protein YqiC | Q46868|YQIC_ECOLI | 48 |
| Formate dehydrogenase, nitrate-inducible, major subunit | P24183|FDNG_ECOLI | 47 |
| Acyl carrier protein | P0A6A8|ACP_ECOLI | 45 |
| Maltose/maltodextrin-binding periplasmic protein | P0AEX9|MALE_ECOLI | 44 |
| Septum site-determining protein MinD | P0AEZ3|MIND_ECOLI | 42 |
| Phosphate-specific transport system accessory protein PhoU | P0A9K7|PHOU_ECOLI | 40 |
| Ribosome-associated inhibitor A | P0AD49|YFIA_ECOLI | 36 |
| DNA-binding protein H-NS | P0ACF8|HNS_ECOLI | 35 |
| RNA-binding protein Hfq | P0A6X3|HFQ_ECOLI | 33 |
| Phosphate transport system permease protein PstA | P07654|PSTA_ECOLI | 32 |
| Galactoside transport system permease protein MglC | P23200|MGLC_ECOLI | 32 |
| Sec translocon accessory complex subunit YajC | P0ADZ7|YAJC_ECOLI | 31 |
| Isoform Beta of Translation initiation factor IF-2 | P0A705-2|IF2_ECOLI | 30 |
| 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase | P62707|GPMA_ECOLI | 30 |
| Peptidoglycan D,D-transpeptidase FtsI | P0AD68|FTSI_ECOLI | 28 |
| Inner membrane protein YjcH | P0AF54|YJCH_ECOLI | 27 |
| HTH-type transcriptional regulator GntR | P0ACP5|GNTR_ECOLI | 27 |
| Histidinol-phosphate aminotransferase | P06986|HIS8_ECOLI | 26 |
| SsrA-binding protein | P0A832|SSRP_ECOLI | 25 |
| 2-dehydro-3-deoxyphosphooctonate aldolase | P0A715|KDSA_ECOLI | 25 |
| Deoxyribose-phosphate aldolase | P0A6L0|DEOC_ECOLI | 25 |
| Ribosome hibernation promoting factor | P0AFX0|HPF_ECOLI | 24 |
| Ribokinase | P0A9J6|RBSK_ECOLI | 24 |
| Probable ATP-dependent helicase l hr | P30015|LHR_ECOLI | 22 |
| Membrane-bound lytic murein transglycosylase B | P41052|MLTB_ECOLI | 21 |
| Uncharacterized protein YjaA | P09162|YJAA_ECOLI | 21 |
| Adenylate kinase | P69441|KAD_ECOLI | 21 |
| Fructose-1,6-bisphosphatase 2 class 2 | P21437|GLPX2_ECOLI | 20 |
| Transcription termination/antitermination protein NusA | P0AFF6|NUSA_ECOLI | 20 |
| Protein name | Symbol | Score (p < 0.05)‡ |
|---|---|---|
| Glutamate decarboxylase alpha | P69908|DCEA_ECOLI | 189 |
| ATP-dependent zinc metalloprotease FtsH | P0AAI3|FTSH_ECOLI | 128 |
| Rod shape-determining protein MreB | P0A9X4|MREB_ECOLI | 109 |
| Uncharacterized protein YibN | P0AG27|YIBN_ECOLI | 101 |
| Outer membrane protein X | P0A917|OMPX_ECOLI | 99 |
| Galactitol 1-phosphate 5-dehydrogenase | P0A9S3|GATD_ECOLI | 91 |
| UPF0381 protein YfcZ | P0AD33|YFCZ_ECOLI | 85 |
| 50S ribosomal protein L31 | P0A7M9|RL31_ECOLI | 83 |
| Biotin carboxylase | P24182|ACCC_ECOLI | 83 |
| GMP synthase [glutamine-hydrolyzing] | P04079|GUAA_ECOLI | 82 |
| Cytochrome bd-I ubiquinol oxidase subunit 1 | P0ABJ9|CYDA_ECOLI | 74 |
| Galactokinase | P0A6T3|GAL1_ECOLI | 74 |
| RNA chaperone ProQ | P45577|PROQ_ECOLI | 71 |
| Protein GrpE | P09372|GRPE_ECOLI | 68 |
| Purine nucleoside phosphorylase | P0ABP8|DEOD_ECOLI | 61 |
| 50S ribosomal protein L21 | P0AG48|RL21_ECOLI | 59 |
| Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex | P0AFG6|ODO2_ECOLI | 58 |
| Sec-independent protein translocase protein TatA | P69428|TATA_ECOLI | 56 |
| Bifunctional protein GlmU | P0ACC7|GLMU_ECOLI | 56 |
| PTS system mannose-specific EIIAB component | P69797|PTNAB_ECOLI | 55 |
| Anaerobic glycerol-3-phosphate dehydrogenase subunit C | P0A996|GLPC_ECOLI | 54 |
| Proline/betaine transporter | P0C0L7|PROP_ECOLI | 52 |
| Pyruvate formate-lyase 1-activating enzyme | P0A9N4|PFLA_ECOLI | 52 |
| Pyruvate/proton symporter BtsT | P39396|BTST_ECOLI | 52 |
| Protein translocase subunit SecY | P0AGA2|SECY_ECOLI | 49 |
| Penicillin-binding protein activator LpoB | P0AB38|LPOB_ECOLI | 49 |
| Signal peptidase I | P00803|LEP_ECOLI | 45 |
| Thiol peroxidase | P0A862|TPX_ECOLI | 45 |
| UPF0307 protein YjgA | P0A8X0|YJGA_ECOLI | 45 |
| Peptidyl-prolyl cis-trans isomerase D | P0ADY1|PPID_ECOLI | 44 |
| 3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase | P0A6Q3|FABA_ECOLI | 44 |
| ATP-dependent protease subunit HslV | P0A7B8|HSLV_ECOLI | 43 |
| Inosine-5'-monophosphate dehydrogenase | P0ADG7|IMDH_ECOLI | 42 |
| Peptide chain release factor RF2 | P07012|RF2_ECOLI | 41 |
| Nucleoside diphosphate kinase | P0A763|NDK_ECOLI | 40 |
| Inositol-1-monophosphatase | P0ADG4|SUHB_ECOLI | 40 |
| Respiratory nitrate reductase 1 gamma chain | P11350|NARI_ECOLI | 40 |
| Succinate dehydrogenase hydrophobic membrane anchor subunit | P0AC44|DHSD_ECOLI | 39 |
| Outer membrane protein assembly factor BamB | P77774|BAMB_ECOLI | 36 |
| Signal recognition particle receptor FtsY | P10121|FTSY_ECOLI | 36 |
| Anaerobic C4-dicarboxylate transporter DcuB | P0ABN9|DCUB_ECOLI | 34 |
| Glucans biosynthesis protein | P33136|OPGG_ECOLI | 34 |
| Adenine phosphoribosyltransferase | P69503|APT_ECOLI | 34 |
| Maltoporin | P02943|LAMB_ECOLI | 34 |
| NADH-quinone oxidoreductase subunit C/D | P33599|NUOCD_ECOLI | 32 |
| ATP-dependent protease ATPase subunit HslU | P0A6H5|HSLU_ECOLI | 32 |
| CDP-diacylglycerol–serine O-phosphatidyltransferase | P23830|PSS_ECOLI | 32 |
| PTS system trehalose-specific EIIBC component | P36672|PTTBC_ECOLI | 31 |
| Transcription termination/antitermination protein NusG | P0AFG0|NUSG_ECOLI | 31 |
| Protein translocase subunit SecF | P0AG93|SECF_ECOLI | 30 |
| Oligopeptide transport system permease protein OppB | P0AFH2|OPPB_ECOLI | 30 |
| Uncharacterized protein YffS | P76550|YFFS_ECOLI | 29 |
| NADH-quinone oxidoreductase subunit J | P0AFE0|NUOJ_ECOLI | 29 |
| Glucosamine-6-phosphate deaminase | P0A759|NAGB_ECOLI | 29 |
| Uncharacterized protein YiaF | P0ADK0|YIAF_ECOLI | 28 |
| Tol-Pal system protein TolQ | P0ABU9|TOLQ_ECOLI | 28 |
| Multidrug export protein EmrA | P27303|EMRA_ECOLI | 27 |
| UPF0246 protein YaaA | P0A8I3|YAAA_ECOLI | 25 |
| DNA-directed RNA polymerase subunit omega | P0A800|RPOZ_ECOLI | 24 |
| ATP-binding/permease protein CydD | P29018|CYDD_ECOLI | 24 |
| Glycine betaine-binding protein YehZ | P33362|YEHZ_ECOLI | 23 |
| NADP-dependent malic enzyme | P76558|MAO2_ECOLI | 23 |
| Multiphosphoryl transfer protein | P69811|PTFAH_ECOLI | 23 |
| Ribose-5-phosphate isomerase A | P0A7Z0|RPIA_ECOLI | 22 |
| Disulfide bond formation protein B | P0A6M2|DSBB_ECOLI | 22 |
| Uncharacterized protein YbjD | P75828|YBJD_ECOLI | 22 |
| NADH-quinone oxidoreductase subunit L | P33607|NUOL_ECOLI | 21 |
| Pyridoxine 5'-phosphate synthase | P0A794|PDXJ_ECOLI | 21 |
Discussion
To our knowledge this is the first study to evaluate the putative effects of CBD on the release of membrane vesicles (MVs) from bacteria and effects of CBD on MV profile, including protein composition. In eukaryotic cells, CBD was recently identified as an effective inhibitor of extracellular vesicle (EV) release both in human cancer cells (Kosgodage et al., 2018, 2019) as well as in the intestinal parasite Giardia intestinalis (Gavinho et al., 2019). Therefore, our present findings may indicate phylogenetically conserved pathways of membrane vesicle release from bacteria to mammals that can be modulated via CBD. Moreover, CBD could enhance the anti-bacterial effect of certain antibiotics in some bacterial types, but also inhibit it in others. This indicates that inhibition of MV release and anti-bacterial action are likely linked, as previously suggested (Tashiro et al., 2010). Indeed, a recent study using indole derivatives has revealed a role for MVs in antibiotic resistance/persistence, in particular in Gram-negative bacteria tested (Agarwal et al., 2019).
Here we report that CBD significantly reduced MV release in E. coli VCS257, a Gram-negative bacterium, but had negligible effects on membrane vesicle release in S. aureus subsp. aureus Rosenbach, a Gram-positive bacterium, as assessed here by in vitro analysis. In addition, we also found that lower doses of CBD had a stronger MV inhibitory effect in E. coli VCS257 than a higher 5 μM dose (p = 0.0063), and such an effect has also previously been observed for EVs in certain cancer cell types (Kosgodage et al., 2018). Biphasic effects of CBD are indeed recognized (Bergamaschi et al., 2011) and may be reminiscent of “hormesis,” an effect we have suggested could explain its more general medical benefits as well as effects on mitochondrial dynamics (Nunn et al., 2013). Interestingly, at the lower 1 μM concentration, CBD significantly increased the release of a 500 nm peak of MVs, as observed by NTA analysis, while this peak was negligible both in the control treated bacteria and those treated with 5 μM CBD. Such an effect of CBD on MV profile, and protein MV profile as observed by proteomic analysis here, may be relevant in the light of recent recognition of the importance of MV size for cellular entry and uptake (Turner et al., 2018) and in line with an increased interest in the research community for the identification and characterization of MV sub-populations (Pérez-Cruz et al., 2016; Turner et al., 2018; Cooke et al., 2019; Toyofuku et al., 2019; Zavan et al., 2019). The approximately 6.5-fold and 2.5-fold decreases in MV release observed after CBD (1 and 5 μm, respectively) treatment from E. coli, compared to non-treated controls, also correlated with a trend in shift toward proportionally larger vesicles released according to NTA analysis and change in protein profile. The exact mechanism for packaging proteins and other reagents in MVs is not fully understood and given the plethora of targets for CBD (Ibeas Bih et al., 2015; Hernández-Cervantes et al., 2017; Pisanti et al., 2017), the exact mechanism of this cannabinoid on MV formation remains subject to further extensive studies. In the current study we have indeed identified a range proteins, including proteins involved in metabolism and antibiotic metabolic processing, which differ in MVs released from E. coli VCS257 treated with CBD, compared to MVs released from non-treated E. coli. Previous studies have discussed the use of MVs for example as drug delivery vehicles (Ellis and Kuehn, 2010; Gujrati et al., 2014; Gerritzen et al., 2017; Jain and Pillai, 2017; Jan, 2017; Wang et al., 2018), while MVs have also been tested as delivery vehicles for targeted gene silencing using siRNA-packaged MVs (Alves et al., 2016). Whether CBD may be utilized for combinatory application with such approaches may also be of putative interest, in addition to its observed effects in this study, in effectively reducing MV release.
In relation to antibiotic activity, cannabinoids including CBD, have been widely studied for their anti-bacterial activity (Wasim et al., 1995; Bass et al., 1996; Appendino et al., 2008; Hernández-Cervantes et al., 2017). For example, C. sativa extracts have previously been shown to have microbicidal activity on various Gram-positive bacteria, including several strains of S. aureus, as well as some Gram-negative bacteria (Wasim et al., 1995; Elphick, 2007; Nissen et al., 2010), with the minimum inhibitory concentrations (MIC) for the main phytocannabinoids, such as CBD, being in the 0.5–5 μM range, which is similar to many modern antibiotics (Van Klingeren and Ten Ham, 1976; Appendino et al., 2008). How precisely CBD may be working as an anti-bacterial agent is still not entirely clear (Appendino et al., 2008), particularly in the light of a plethora of targets for CBD (Ibeas Bih et al., 2015; Hernández-Cervantes et al., 2017), while structure-activity studies indicate that the ability of plant-derived phenolic compounds to interact with membranes and the existence of electrophilic functional groups are important (Miklasinska-Majdanik et al., 2018). Hitherto though, no association has been made into a putative regulatory effect of cannabinoids on bacterial membrane vesicle release. Furthermore, as the current study has revealed changes in proteomic profile of MVs released from E. coli VCS257 following CBD treatment, such findings may inform anti-bacterial effects of CBD. Using LC-MS/MS analysis to assess changes in protein profile of MVs from CBD treated and untreated E. coli, respectively, five proteins were found to be absent in the 1 μM CBD treated MVs and 4 proteins were absent in the 5 μM CBD treated MVs, compared to control untreated E. coli MVs. Out of these, 2 proteins overlapped between the two CBD treatments. In addition, comparing 1 and 5 μM CBD treated E. coli MVs, 26 protein hits were unique to MVs released following the 1 μM CBD treatment and 68 protein hits to MVs released following the 5 μM CBD treatment. Using STRING analysis, PPI enrichment p-value was found to be p = 0.0204 for proteins identified as unique to MVs from the 1 μM CBD treatment and p = 1.56 × 10−6 for proteins identified as unique to MVs from the 5 μM CBD. This indicates that for both treatments these proteins have significantly more interactions among themselves, than what would be expected for a random set of proteins of similar size, drawn from the genome. Such enrichment indicates that the proteins are at least partially biologically connected, as a group. Protein networks are represented showing biological GO pathways and KEGG pathways, respectively, in Supplementary Figures 3, 4 for proteins specific to EVs from E. coli after 1 and 5 μM CBD treatment, respectively. Proteins identified are related to metabolic processes, cellular respiration and antibiotic functions (Supplementary Figures 3A,B, 4A,B).
When assessing the effectivity of CBD to enhance susceptibility of Gram-positive and Gram-negative bacterial species to a range of antibiotics, CBD-mediated MV inhibition rendered E. coli VCS257 significantly more sensitive to erythromycin, vancomycin and rifampicin and somewhat to kanamycin, but did not augment the bactericidal effects observed for colistin. This was somewhat unexpected, given a previous study showing that MVs isolated from the E. coli strain MG1655 could protect bacteria against membrane-active antibiotics such as colistin (Kulkarni et al., 2015). Our finding, that CBD did not sensitize E. coli further to colistin, when applied in combination with this antibiotic, may arise from the fact that a different strain of E. coli (VCS257) was used in the current study, compared to in the study by Kulkarni et al. (2015). It has also been previously shown that the presence of calcium decreases the bactericidal effect of colistin on Paenibacillus polymyxa, suggesting a role for Ca2+ in generating a protective barrier against colistin (Yu et al., 2015). As CBD is known to modulate calcium (Rimmerman et al., 2013) it can be postulated that this may interfere with the mode of action of colistin. Our findings also indicate that combinatory application of CBD is not effective for all antibiotics, which may possibly be explained by their different modes of action. Importantly, zones of inhibition were observed in the plates which were only treated with the CBD discs in the presence of E. coli, and this clearly revealed the antibacterial property of CBD.
Interestingly, CBD did increase antibacterial effects of vancomycin on E. coli, in spite of vancomycin's limited effectiveness on Gram-negative species, also seen here by the fact that vancomycin alone did not result in a halo around the diffusion disk for E. coli. Therefore, CBD seems to overcome previously established resistance of E. coli to vancomycin, which has reported to partly be due to its inability to significantly penetrate the outer membrane (Zhou et al., 2015). It may also be important to note that erythromycin, rifampicin and kanamycin inhibit protein synthesis, whereas vancomycin is a glycopeptide that inhibits cell biosynthesis in Gram-positive bacteria, while colistin binds to the outer membrane of Gram-negative bacteria, disrupting it. Thus, these antibiotics display very different modes of action.
In the Gram-positive bacterium S. aureus subsp. aureus Rosenbach, CBD increased bactericidal activity of kanamycin only. The reduced ability of CBD to sensitize this Gram-positive bacterium to antibiotics, compared to the significantly higher effects in the Gram-negative bacterium, tallied in with CBD's ability to regulate MV-release, indicating a relevant contribution of MVs to antibiotic resistance. Roles for MVs in protecting biofilms via adsorption of antimicrobial agents have indeed been previously recognized (Schooling and Beveridge, 2006; Manning and Kuehn, 2011; Toyofuku et al., 2019). This also indicates that MV-inhibitors that target membrane vesicles from specific bacteria species, such as CBD here, could be applied in combination with selected antibiotics for tailored antibiotic treatment to tackle antibiotic resistance.
Conclusions
CBD effectively inhibited MV release from the Gram-negative bacterium E. coli VCS257, exhibiting a stronger MV-inhibiting effect at lower dose. In addition, CBD modulated MV protein profiles of E. coli following 1 h treatment. CBD did not have significant effects on MV release in the Gram-positive bacterium S. aureus subsp. aureus Rosenbach. When applied in combination with a range of antibiotics, CBD increased anti-bacterial effects of selected antibiotics, depending on bacteria type. CBD, in combination with specific antibiotics, may thus possibly be used as an adjuvant to selectively target bacteria to sensitize them to antibiotic treatment and reduce antibiotic resistance.
Data Availability
All datasets generated for this study are included in the manuscript and/or the Supplementary Files.
Acknowledgements
This work was supported in parts by a University of Westminster Start-up Grant to SL and an unrestricted grant from GW Pharmaceuticals. Thanks are due to the Guy Foundation for funding the purchase of equipment utilized in this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2019.00324/full#supplementary-material